Safety of baricitinib in East Asian patients with moderate-to-severe active rheumatoid arthritis: An integrated analysis from clinical trials.

Ying-Chou ChenDae Hyun YooChang Keun LeeKo-Jen LiJi-Eon WonWen-Shuo WuJinglin ZhongClaudia NicolayChad Daniel WallsYoshiya Tanaka

Published in: International journal of rheumatic diseases (2019)

Integrated data show that baricitinib is well-tolerated in EA patients with moderate-to-severely active RA in the context of demonstrated efficacy, which is generally consistent with safety results of the overall study population.

Keyphrases

rheumatoid arthritis
clinical trial
high intensity
disease activity
ankylosing spondylitis
early onset
electronic health record
randomized controlled trial
systemic lupus erythematosus
machine learning